Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05455021

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: REACTIVATE I

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) after Sub-optimal percutaneous transluminal angioplasty (PTA) or Atherectomy: REACTIVATE I

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Flinders Medical Center, Adelaide, South Australia, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects for this study must meet all of the following general eligibility criteria

AND the answer must be "YES" to all general inclusion criteria:

  • Subject (or Legal Guardian) is willing and able to provide consent before any study-specific tests or procedures are performed and agree to attend all required follow-up visits.
  • Male or female subject of at least 18 years of age.
  • Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or 4.
  • Has screen failed from the ACTIVATE II study due to the presence of Grade C or D dissection(s).

Exclusion criteria

  • Life expectancy, documented in the Investigator's opinion, of less than 1 year.
  • Cerebrovascular accident (CVA) or transient ischemic attack (TIA) or cardiac event (e.g., PCI for STEMI/NSTEMI, unstable angina) within 6 months prior to the index procedure.
  • Chronic renal insufficiency with serum creatinine ≥ 2.5 mg/dL or eGFR <45 ml/min within 30 days prior to the index procedure or treatment with peritoneal or hemodialysis.
  • Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 within 30 days prior to the index procedure or has a history of bleeding diathesis.
  • Receiving oral or intravenous immunosuppressive therapy.
  • Subject has white blood cell (WBC) count < 3.0 (3,000 cells/mm3) within 30 days prior to the index procedure.
  • History of major amputation in the target limb.
  • Any major intervention planned at the index procedure or within 30 days post-index procedure including treatment of contralateral limb.
  • Subject is pregnant, breastfeeding, or planning to become pregnant in the next 30 days. Subjects (male and female) of childbearing potential must agree to use effective birth control measures for 30 days after the index procedure.

Treatment and study plan

Vessel Restoration System (VRS)

Combination Product

The VRS includes the following components:

  • VRS 10-8-10 Dimer Coated Balloon Catheter
  • VRS Light Fiber
  • VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements.

Primary outcomes

  1. An acute reduction in arterial dissections

    Time frame: 12 months

    Reduction in arterial dissection(s) of at least one grade.

  2. Primary Patency as assessed by Doppler Ultrasound (DUS) and freedom from CD-TLR at 1 Year

    Time frame: 12 months

    Primary Patency as assessed by Doppler Ultrasound (DUS)

Secondary outcomes

  1. Technical Success

    Time frame: 12 months

    Technical success is defined by successful delivery of the VRS

  2. Procedural Success

    Time frame: 12 months

    Procedural Success is defined as an acute reduction in arterial dissection(s)

  3. Clinical Success

    Time frame: 36 months

    Clinical success is defined as freedom from CD-TLR

  4. Safety Measure

    Time frame: 72 months

    Frequency of MAEs

  5. Hemodynamic Improvement

    Time frame: 36 months

    Rate of hemodynamic improvement ABI

  6. Rutherford Classification

    Time frame: 36 months

    As assessed by changes in Rutherford Class

  7. Quality of Life Measure

    Time frame: 72 months

    Quality of life (QOL) assessment by EQ-5D

Other outcomes

  1. Major Adverse Limb Events

    Time frame: 36 months

  2. Reintervention for treatment of thrombosis of the target vessel or embolization to its distal Vasculature

    Time frame: 36 months

  3. Major Vascular Complications

    Time frame: 36 months

Sponsors and collaborators

Lead sponsor

Alucent Biomedical

Industry

Registry information

Acronym: REACTIVATE I

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Jul 13, 2022
Registry last updated
Jan 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.